Verified factor-similar pair

SCHM vs XJH

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
89
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • SCHM has the higher backtested relative Sharpe (0.918 vs 0.705).
  • SCHM has the lower published fee (0.04% vs 0.12%).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

SCHM

Schwab U.S. Mid-Cap ETF
SMB
Adj. R2
0.947
Rel. Sharpe
0.918
Mkt beta
1.02
AUM
US$13.6B
MER
0.04%
Valuation
116

XJH

iShares ESG Select Screened S&P Mid-Cap ETF
SMB
Adj. R2
0.942
Rel. Sharpe
0.705
Mkt beta
1.02
AUM
US$362M
MER
0.12%
Valuation
117

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
SCHM
+0.42
|t|
+10.8
XJH
+0.54
|t|
+8.6
diff -0.12
HML
SCHM
+0.13
|t|
+3.5
XJH
+0.19
|t|
+3.2
diff -0.06
RMW
SCHM
+0.03
|t|
+0.7
XJH
+0.19
|t|
+2.9
diff -0.16
CMA
SCHM
-0.01
|t|
-0.2
XJH
-0.01
|t|
-0.1
diff -0.00
UMD
SCHM
+0.03
|t|
+1.2
XJH
+0.01
|t|
+0.2
diff +0.02

Why This Pair Matches

Exposure level
87
Exposure shape
98
Mkt beta diff
0.01
Rel. Sharpe diff
0.213

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

SCHM fund page XJH fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.